Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion, inactivated, quadrivalent) (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaxigrip Quadrivalent (also known as VaxigripTetra) is a quadrivalent split-virion inactivated influenza vaccine (IIV4) developed by Sanofi Pasteur. It is designed to provide broad protection against seasonal influenza by including hemagglutinin (HA) antigens from four different influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine is produced by propagating the viruses in embryonated chicken eggs, followed by formaldehyde inactivation, purification via zonal centrifugation, and splitting into subvirion forms. It stimulates the immune system to produce protective antibodies against the specific HA antigens. It is indicated for the prevention of influenza in adults and children, typically administered as a single intramuscular injection.
- Brand names
- Vaxigrip QuadrivalentVaxigripTetra
- Other names
- IIV4IIV-4IIV 4quadrivalent split-virion inactivated influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (split virion, inactivated, quadrivalent) (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion, inactivated, quadrivalent) (Sanofi).